FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005985565> ?p ?o ?g. }

• W3005985565 abstract "Abstract Background Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence based on the 70-gene risk of recurrence signature (70-GS, MammaPrint) and the 80-gene molecular subtype signature (80-GS, BluePrint) in early stage breast cancer patients. Methods IMPACt, a prospective, case-only study, enrolled 452 patients between November 2015 and August 2017. The primary objective population included 358 patients with stage I-II, hormone receptor-positive, HER2-negative breast cancer. The recommended treatment plan and physician confidence were captured before and after receiving results for 70-GS and 80-GS. Treatment was started after obtaining results. The distribution of 70-GS High Risk (HR) and Low Risk (LR) patients was evaluated, in addition to the distribution of 80-GS compared to IHC status. Results The 70-GS classified 62.5% ( n = 224/358) of patients as LR and 37.5% ( n = 134/358) as HR. Treatment decisions were changed for 24.0% ( n = 86/358) of patients after receiving 70-GS and 80-GS results. Of the LR patients initially prescribed CT, 71.0% (44/62) had CT removed from their treatment recommendation. Of the HR patients not initially prescribed CT, 65.1% (41/63) had CT added. After receiving 70-GS results, CT was included in 83.6% ( n = 112/134) of 70-GS HR patient treatment plans, and 91.5% ( n = 205/224) of 70-GS LR patient treatment plans did not include CT. For patients who disagreed with the treatment recommended by their physicians, most (94.1%, n = 16/17) elected not to receive CT when it was recommended. For patients whose physician-recommended treatment plan was discordant with 70-GS results, discordance was significantly associated with age and lymph node status. Conclusions The IMPACt trial showed that treatment plans were 88.5% ( n = 317/358) in agreement with 70-GS results, indicating that physicians make treatment decisions in clinical practice based on the 70-GS result. In clinically high risk, 70-GS Low Risk patients, there was a 60.0% reduction in treatment recommendations that include CT. Additionally, physicians reported having greater confidence in treatment decisions for their patients in 72% ( n = 258/358) of cases after receiving 70-GS results. Trial registration “Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry” ( NCT02670577 ) retrospectively registered on Jan 27, 2016." @default.
• W3005985565 created "2020-02-24" @default.
• W3005985565 creator A5000862048 @default.
• W3005985565 creator A5002529868 @default.
• W3005985565 creator A5022925854 @default.
• W3005985565 creator A5032020875 @default.
• W3005985565 creator A5036435891 @default.
• W3005985565 creator A5038361571 @default.
• W3005985565 creator A5042088246 @default.
• W3005985565 creator A5055894943 @default.
• W3005985565 creator A5057875896 @default.
• W3005985565 creator A5063800598 @default.
• W3005985565 creator A5070120524 @default.
• W3005985565 creator A5082378015 @default.
• W3005985565 creator A5090359583 @default.
• W3005985565 creator A5090789911 @default.
• W3005985565 date "2020-01-31" @default.
• W3005985565 modified "2023-10-16" @default.
• W3005985565 title "MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial" @default.
• W3005985565 cites W1998096683 @default.
• W3005985565 cites W2032968026 @default.
• W3005985565 cites W2050056063 @default.
• W3005985565 cites W2059786375 @default.
• W3005985565 cites W2070237809 @default.
• W3005985565 cites W2071663583 @default.
• W3005985565 cites W2074619860 @default.
• W3005985565 cites W2099354636 @default.
• W3005985565 cites W2107694321 @default.
• W3005985565 cites W2109937431 @default.
• W3005985565 cites W2116188625 @default.
• W3005985565 cites W2118168312 @default.
• W3005985565 cites W2118355289 @default.
• W3005985565 cites W2128985829 @default.
• W3005985565 cites W2133615432 @default.
• W3005985565 cites W2149900235 @default.
• W3005985565 cites W2151640153 @default.
• W3005985565 cites W2154976095 @default.
• W3005985565 cites W2156273110 @default.
• W3005985565 cites W2160450758 @default.
• W3005985565 cites W2169432501 @default.
• W3005985565 cites W2192081476 @default.
• W3005985565 cites W2266198524 @default.
• W3005985565 cites W2517421365 @default.
• W3005985565 cites W2530010510 @default.
• W3005985565 cites W2600992170 @default.
• W3005985565 cites W2747379890 @default.
• W3005985565 cites W2750373674 @default.
• W3005985565 cites W2766888734 @default.
• W3005985565 cites W2915351954 @default.
• W3005985565 doi "https://doi.org/10.1186/s12885-020-6534-z" @default.
• W3005985565 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6995096" @default.
• W3005985565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32005181" @default.
• W3005985565 hasPublicationYear "2020" @default.
• W3005985565 type Work @default.
• W3005985565 sameAs 3005985565 @default.
• W3005985565 citedByCount "42" @default.
• W3005985565 countsByYear W30059855652020 @default.
• W3005985565 countsByYear W30059855652021 @default.
• W3005985565 countsByYear W30059855652022 @default.
• W3005985565 countsByYear W30059855652023 @default.
• W3005985565 crossrefType "journal-article" @default.
• W3005985565 hasAuthorship W3005985565A5000862048 @default.
• W3005985565 hasAuthorship W3005985565A5002529868 @default.
• W3005985565 hasAuthorship W3005985565A5022925854 @default.
• W3005985565 hasAuthorship W3005985565A5032020875 @default.
• W3005985565 hasAuthorship W3005985565A5036435891 @default.
• W3005985565 hasAuthorship W3005985565A5038361571 @default.
• W3005985565 hasAuthorship W3005985565A5042088246 @default.
• W3005985565 hasAuthorship W3005985565A5055894943 @default.
• W3005985565 hasAuthorship W3005985565A5057875896 @default.
• W3005985565 hasAuthorship W3005985565A5063800598 @default.
• W3005985565 hasAuthorship W3005985565A5070120524 @default.
• W3005985565 hasAuthorship W3005985565A5082378015 @default.
• W3005985565 hasAuthorship W3005985565A5090359583 @default.
• W3005985565 hasAuthorship W3005985565A5090789911 @default.
• W3005985565 hasBestOaLocation W30059855651 @default.
• W3005985565 hasConcept C121608353 @default.
• W3005985565 hasConcept C126322002 @default.
• W3005985565 hasConcept C143998085 @default.
• W3005985565 hasConcept C146357865 @default.
• W3005985565 hasConcept C151730666 @default.
• W3005985565 hasConcept C2780140570 @default.
• W3005985565 hasConcept C2908647359 @default.
• W3005985565 hasConcept C29456083 @default.
• W3005985565 hasConcept C44249647 @default.
• W3005985565 hasConcept C530470458 @default.
• W3005985565 hasConcept C71924100 @default.
• W3005985565 hasConcept C86803240 @default.
• W3005985565 hasConcept C99454951 @default.
• W3005985565 hasConceptScore W3005985565C121608353 @default.
• W3005985565 hasConceptScore W3005985565C126322002 @default.
• W3005985565 hasConceptScore W3005985565C143998085 @default.
• W3005985565 hasConceptScore W3005985565C146357865 @default.
• W3005985565 hasConceptScore W3005985565C151730666 @default.
• W3005985565 hasConceptScore W3005985565C2780140570 @default.
• W3005985565 hasConceptScore W3005985565C2908647359 @default.
• W3005985565 hasConceptScore W3005985565C29456083 @default.
• W3005985565 hasConceptScore W3005985565C44249647 @default.
• W3005985565 hasConceptScore W3005985565C530470458 @default.
• W3005985565 hasConceptScore W3005985565C71924100 @default.

• next